Bone Therapeutics is always looking to build high-value strategic collaborations to create the next generation of cell therapy products. The Company has several research collaborations on some of its key projects with industrial and academic partners.
Asahi Kasei Corporation (Japan - Tokyo: 3407) : Bone Therapeutics has signed an exclusive, royalty-bearing license agreement with one of Japan’s leading industrial companies, Asahi Kasei Corporation. The license agreement covers the development and commercialisation of Bone Therapeutics’ autologous bone cell therapy product, PREOB ® , in Japan.
Under the terms of the agreement, Asahi Kasei will obtain exclusive rights to develop, register and commercialise PREOB ® for the treatment of osteonecrosis of the hip with the potential for other orthopaedic and bone applications in Japan. Bone Therapeutics will share its patented proprietary manufacturing expertise for the expansion and differentiation of stem cells into bone-forming cells in preparation for continued clinical development by Asahi Kasei in Japan. In addition, Bone Therapeutics has also granted Asahi Kasei an option to negotiate an exclusive license for the development and commercialization of PREOB ® in Korea, China and Taiwan.
Kasios SPRL (BE, FR) : Bone Therapeutics has entered into a collaboration with Kasios SPRL to develop a novel product for spinal fusion procedures, in which Bone Therapeutics' allogeneic product, ALLOB ®
Fujifilm Manufacturing Europe B.V. (NL) : Bone Therapeutics collaborates with Fujifilm Manufacturing Europe B.V. to identify the therapeutic advantages of the combined use of recombinant-collagen scaffold and cells for orthopaedic applications.
Sirris and Image Analysis Ltd. : Bone Therapeutics collaborates with Sirris and Image Analysis Ltd. to assess the feasibility of developing 3D patient-tailored bioresorbable bone tissue-engineered products for the reconstruction of bone defects.
Université libre de Bruxelles (ULB), Université de Liège (ULg) and Centre hospitalier de Liège: Bone Therapeutics has a core academic, research and license collaboration with ULB and entered into a license agreements with the ULB, the ULg and the Centre hospitalier de Liège.
CHU de Liège (Sart-Tilman): Bone Therapeutics works in collaboration with the LTCG, the accredited Tissue Bank from the CHU (Sart-Tilman).
Centre for Microscopy and Molecular Imaging (CMMI): Bone Therapeutics is collaborating with CMMI for several of its research projects.
Bone Therapeutics also receives support from Regional and European public funds and the WBC incubator.
For more information on partnership opportunities with Bone Therapeutics, please contact Bone Therapeutics' Business Development Department at firstname.lastname@example.org .